Navigation Links
Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
Date:7/10/2008

ANTONY, France, July 10 /PRNewswire-FirstCall/ --

- 1st Half-Year Sales Up 16%

- Revision Upwards of 2008 Sales Growth Guidance: (greater than or equal to)12%

EUR millions 2006 2007 07/06 2008 08/07

EURM %Sales EURM %Sales % EURM %Sales %

change change

Southern Europe (1) 20.5 72 23.2 72 13 26.8 71 15

Other EU countries (2) 6.9 24 7.7 24 11 9.3 24 20

Other markets 1.2 4 1.3 4 15 2.0 5 47

SLIT 21.8 76 25.1 77 15 30.4 80 21

SCIT 5.4 19 5.6 18 5 6.1 16 7

Other products 1.5 5 1.5 5 (0) 1.6 4 4

Total Q2 sales 28.6 100 32.2 100 13 38.0 100 18

Southern Europe (1) 48.1 75 56.5 76 18 64.7 75 14

Other EU countries (2) 13.7 21 15.8 21 15 18.6 21 18

Other markets 2.4 4 2.5 3 5 3.7 4 46

SLIT 49.4 77 59.7 80 21 71.3 82 19

SCIT 11.6 18 11.8 16 2 12.3 14 4

Other products 3.2 5 3.2 4 3 3.4 4 6

Total H1 sales 64.2 100 74.8 100 17 87.0 100 16

(1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included

2008 second quarter sales recorded strong growth in all markets (+18% vs +13% in 2007). Eastern European markets and other markets outside Europe made a significant contribution to this growth. The most buoyant segment of the market remained desensitisation via the sublingual route (SLIT, +21%, vs +15% in 2007) whose reputation was enhanced by the launch of allergen tablets.

Cumulated sales for the first half-year increased by 16% compared to the first half 2007, when growth was already particularly strong (+ 17%). This good performance has enabled the Group to revise its sales growth guidance upwards to growth of at least 12% in 2008 (vs (greater than or equal to)10% previously), boosted by the growing success of the sublingual route, in which Stallergenes continues to strengthen its leadership.

The commercial launch of ORALAIR(R) Grasses for adults will take place in Germany in the next few weeks, following the grant, on 24 June 2008, of the marketing authorisation. The request for a paediatric extension of ORALAIR(R) Grasses has been filed with the Paul Ehrlich Institute. The application for clinical studies for ORALAIR(R) Grasses in the US will be filed in July.

The 2008 first half-year financial results will benefit from a strong level of activity and will show a marked improvement compared to 2007. These results will be released on 27 August 2008.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitisation therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitisation treatment, Stallergenes devotes 16% of its turnover to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitisation tablets.

In 2007, Stallergenes had a turnover of 147 million euros and provided desensitisation treatments to more than 500,000 patients.

Stallergenes is listed in Euronext Paris (Compartment B) and

is part of the sample composing the SBF 120 index.

ISIN Code: FR0000065674

Reuters Code: GEN.PA

Bloomberg Code: GEN.FP

Additional information is available on http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
2. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
3. Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets
4. Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe
5. Hoviones Sales Grow 11%
6. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
7. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
8. Increasing Sales Productivity Through Superior Sales Force Performance Management
9. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
10. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
11. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):